Biosimilar Contract Manufacturing Market Size and Trends

The Global Biosimilar Contract Manufacturing Market is estimated to be valued at USD 10.70 Bn in 2024 and is expected to reach USD 30.03 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 16% from 2024 to 2031.

Key Takeaways of the Biosimilar Contract Manufacturing Market:

The recombinant non-glycosylated proteins segment is expected to contribute the highest share of the market with a share of 52.1% in 2024.
The oncology segment is expected to contribute the highest share of the market with 31.1% in 2024.
The mammalian manufacturing segment is expected to contribute the highest share of the market with 58.1% in 2024.
North America is expected to top the market with 37.2% share, followed by Asia Pacific with 27.7% share in 2024.

Market Overview:

The market growth is attributed to the rising demand for biosimilar drugs due to the increasing prevalence of chronic diseases. In addition, the expiration of patents for biologic drugs and rising demand for affordable healthcare are expected to provide market players with lucrative opportunities. However, high costs associated with biosimilar development and manufacturing may hamper the market growth.

Biosimilar Contract Manufacturing Market Concentration By Players

To learn more about this report, Request sample copy

Key Developments:

On May 2024, Boehringer Ingelheim Biopharmaceuticals GmbH, a global leader in biopharmaceuticals known for its innovative medicines and therapies, announced a strategic partnership with Quallent Pharmaceuticals, a pharmaceutical company specializing in global distribution and healthcare solutions
On May, 2024, Boehringer Ingelheim, a global leader in pharmaceuticals, announced a partnership with Quallent Pharmaceuticals to enhance access to its citrate-free biosimilar adalimumab-adbm, a treatment for chronic inflammatory diseases. This collaboration aims to increase availability and affordability of the biosimilar in the U.S., supporting Boehringer Ingelheim’s commitment to improving healthcare access and lowering costs for patients and the healthcare system.
On September, 2023, Abbott, a global healthcare leader, announced a strategic agreement with mAbxience Holdings S.L., a Spain-based biotech company, to commercialize several biosimilars in emerging markets. Abbott will register and distribute these biosimilars, focusing on oncology, women’s health, and respiratory diseases, in key regions across Latin America, Southeast Asia, the Middle East, and Africa. The first biosimilars are expected to launch as early as 2025. This collaboration expands Abbott's portfolio and aims to improve access to affordable treatments in underserved regions.
In June 2023, Samsung Biologics, a leading contract manufacturing organization (CMO) based in South Korea, and global pharmaceutical company, Pfizer, announced a strategic partnership on June 8, 2023, to enhance the manufacturing of Pfizer’s biosimilars portfolio. The agreement focuses on large-scale production for biosimilars in oncology, inflammation, and immunology.

Top Strategies Followed by Global Biosimilar Contract Manufacturing Market Players

Established Players: Leading companies in the global biosimilar contract manufacturing market focus heavily on research and development to drive innovation. They invest extensively in R&D to develop high-performance biosimilar drugs with improved efficacy.
- For instance, in March 2024, Merck & Co. allocated approximately 50.8% of its total revenue, amounting to USD 30.5 billion, towards R&D, reflecting a significant commitment to advancing biologics and biosimilars
Mid-Level Players: Mid-sized companies aim to deliver quality and affordable biologics and biosimilars. They target price-sensitive customer segments by offering cost-competitive solutions. These players invest in automation and digital technologies to optimize production processes.
- In October 2024, Teva Pharmaceuticals and mAbxience have signed a global licensing agreement to develop an anti-PD-1 oncology biosimilar.
Small-Scale Players: Small biosimilar manufacturers focus on specialized market areas left untapped by larger competitors. They develop niche products targeting rare diseases, specific therapeutic areas, or regional markets.
- For instance, Biocon focuses on developing biosimilars for diabetes and oncology, addressing the growing demand in these segments, particularly in emerging markets

Emerging Startups - Global Biosimilar Contract Manufacturing Industry Ecosystem

Innovative Technologies: Several biosimilar startups are developing innovative technologies like smart biosensors and AI solutions. For example, ‘BioX’ uses AI to accelerate cell-line development. Its neural networks help achieve a 10x increase in recombinant protein yields. Another startup ‘Biotech Labs’ is commercializing an implantable biosensor that monitors insulin levels in real-time via a smartphone app. Such advanced technologies have potential to significantly improve production efficiencies and patient outcomes.
Sustainable Solutions: Some emerging companies focus on sustainability. ‘GreenBio’ utilizes agricultural waste as raw material for monoclonal antibody production. It has successfully produced two biosimilars with over 90% recycled materials content. ‘EcoMeds’ is commercializing a biodegradable polymer alternative to glass vials using plant cellulose.